Strategy shareholders face dilution drag despite brighter bitcoin forecasts, TD Cowen says
TD Cowen raised its bitcoin forecasts but kept its $260 price target on Strategy (MSTR) unchanged, saying dilution and the company's financial obligations will likely limit upside for its shareholders.
Analysts Lance Vitanza and Jonnathan Navarrete maintained their Buy rating, arguing that higher bitcoin prices should help boost Strategy's earnings potential. However, its preferred-stock repurchases and reserve building could eat into those gains for MSTR holders.
"Capital structure expansion and associated dilution temper the per-share benefit," the analysts wrote in Thursday's report.
Strategy shares fell roughly 2.5% to $150, leaving them down nearly 5% year to date. The stock has nevertheless recovered from late June through mid-August, when it struggled to break above $100.
TD Cowen's target implies roughly 73% upside from its current price.
More bitcoin against competing claims
Buying more bitcoin doesn't necessarily translate into larger gains for Strategy shareholders, the analysts said. Investors also need to account for the company's debt and preferred shares, including STRC, STRF and STRD, whose holders have claims ahead of common MSTR shareholders.
After factoring those in, bitcoin ownership per MSTR share has been "less robust," TD Cowen said.
Strategy is using some of the money it raises to build cash reserves and support its suite of preferred shares, rather than immediately buying bitcoin. That could help attract investors and fund future purchases, but leaves less money to buy bitcoin today.
Strategy's valuation has recovered to roughly one times net asset value after falling as low as 0.63 in June, according to Saylor Tracker. Its bitcoin holdings, now at an even 848,000 BTC, carry roughly $4.5 billion in unrealized profits.
Brighter bitcoin projections
TD Cowen's updated model puts bitcoin near $109,000 at the end of 2026, and $280,000 by 2029.
That outlook is more bullish than QCP Capital's fourth-quarter base case of $80,000 to $90,000.
Bitcoin was trading near $81,300 on Thursday and remains down 9% year-to-date despite its recent recovery.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Reports of iPhone production cuts send Apple shares lower
October 9 – According to Nikkei Asia (link), Apple has asked its suppliers to cut production of the new iPhone 18 Pro model due to weak demand, resulting in Apple (AAPL.O) shares falling 1.8% in premarket trading to $334.21. The report states that, against the backdrop of soaring memory chip costs and rising prices, the component orders for October have been reduced by at least 15% compared to initial requirements. Apple has not yet responded to a Reuters request for comment. The current stock price is about 1% lower than the all-time intraday high of $345.34 reached on September 22. According to data compiled by the London Stock Exchange Group (LSEG), the average rating from 43 analysts covering the stock is "Buy," with a median target price of $330. (For the convenience of non-English speakers, Reuters provides automated translations of its report into several other languages. As automated translations may contain errors or lack the required context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for reader convenience. Reuters accepts no liability for any damage or loss resulting from use of the automated translation function.)
Citi maintains a “Neutral” rating on DocuSign (DOCU.O): IAM platform migration shows initial effectiveness, double-digit growth still needs "validation"
Citi published a research report maintaining a "Neutral" rating on the e-signature and agreement cloud platform DocuSign, with a target price of $72.
Humana shares soar as it becomes the biggest beneficiary of the 2027 Medicare star ratings.
Reuters, October 9 – In pre-market trading on Friday, shares of Humana (stock code: HUM.N) rose by 15%. Analysts said the health insurer is set to be the biggest beneficiary of the new 2027 Medicare Advantage star ratings. Humana stated that, with improvements in healthcare quality and member experience indicators, 95% of its Medicare Advantage members will be enrolled in plans rated four stars or higher by 2027, a substantial jump from 20% in 2026 (link). JPMorgan analysts noted that they had previously projected this ratio to be between 60% and 70%. The U.S. Department of Health and Human Services uses a one- to five-star scale to rate Medicare Advantage and prescription drug plans. Higher ratings lead to government bonuses worth billions of dollars and can help attract more members. Analysts noted that Humana’s ratings performance outpaced its larger competitors: JPMorgan expects the proportion of UnitedHealth Group’s (UNH.N) plans rated four stars or higher to decrease from 81% to about 67%, while CVS Health’s (CVS.N) ratio will fall from 84% to about 70%. The U.S. Department of Health and Human Services said Thursday night that, overall, about 71% (link) of Medicare Advantage prescription drug plan enrollees will be in contracts rated four stars or higher in 2027. Evercore ISI analyst Elizabeth Anderson said that Humana had improved in prescription drug plan quality, health plan quality, and readmission rates. She added, “This improvement reflects management’s increased focus on these metrics over the past year.” Health insurers provide Medicare Advantage plans for the government to adults aged 65 and older and people with disabilities.
Illia Polosukhin: NEAR accounts can achieve quantum resistance through key updates
Crypto prices
More
